A decline in R&D investment in neglected tropical diseases threatens progress toward critical targets. For over 20 years, one nonprofit has led research on lesser-known diseases and is now seeking new ...

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D ...

South Africa’s research and development funding, human resource development and infrastructure agency, the National Research Foundation (NRF), and the FirstRand Empowerment Foundation (FREF), have ...

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to ...

Industry-led aviation and railways partnerships run nine out of the ten largest Horizon Europe innovation projects, at least ...

Japan began negotiations to join Horizon Europe. If successful, it would mark the first time the country has been fully ...

These actions could postpone NIH-funded clinical trials and create cash flow issues for domestic biotech companies.

If funding stops, those gains simply won’t materialize. There’s good reason for concern: Overall investment in R&D for neglected diseases in 2023 was $3.7 billion, down from a high of $4.7 ...

Royalty Pharma (RPRX) announced that it has entered into an agreement with Biogen (BIIB) to provide research and development funding of up to $250M for litifilimab, a first-in-class ...

Royalty Pharma to provide R&D investment of up to $250 million for Biogen's litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus. NEW ...